Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL)

Swaminathan P Iyer, LaQuisa Hill, Steven Horwitz, Salvia Jain, Christina Poh, Julie M. Vose, Malcolm K. Brenner, Maksim Mamonkin, Sarah Hein, Federica Giordano, Alice Bexon

Blood (2024) 144 (Supplement 1): 7223.

https://doi.org/10.1182/blood-2024-201523

Published: 2024

Journal Articles

Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy

Alan Williams, Rina Mbofung, Daniel Morales-Mantilla, Brian Groff, Alison O'Connor, Binzhong Li, Ramesh Janani, Betsy Rezner, Mark Jelcic, Yijia Pan, Tom Lee, Karl-Johan Malmberg, Maksim Mamonkin, John Goulding, Jode Goodridge, Bahram Valamehr

Blood (2024) 144 (Supplement 1): 503.

https://doi.org/10.1182/blood-2024-210846

Published: 2024

Journal Articles

Targeting IDH2 R140Q and other neoantigens in acute myeloid leukemia

Wingchi K. Leung, Alejandro G. Torres Chavez, Matthew French-Kim, Paul Shafer, Maksim Mamonkin, LaQuisa C. Hill, Manik Kuvalekar, Yovana Velazquez, Ayumi Watanabe, Norihiro Watanabe, Valentina Hoyos, Premal Lulla, Ann M. Leen

Blood (2024) 143 (17): 1726–1737.

https://doi.org/10.1182/blood.2023021979

Published: 2024

Includes: Supplemental data

Journal Articles

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

Blood (2024) 143 (13): 1231–1241.

https://doi.org/10.1182/blood.2023022204

Published: 2024

Includes: Supplemental data

Journal Articles

Combining Apoptotic Resistance and Cytokine Signaling to Improve Persistence and Anti-Tumor Activity of CAR Vδ2 T Cells In Vivo

Leonard Leong, Mansi Narula, Helen Elisabeth Heslop, Malcolm K. Brenner, Maksim Mamonkin, Norihiro Watanabe

Blood (2023) 142 (Supplement 1): 3440.

https://doi.org/10.1182/blood-2023-187658

Published: 2023

Journal Articles

Allogeneic Veto-CAR CD8 T Cells Enabling Prolonged Graft Survival, Anti-Tumor Specificity, and Low Risk of Graft Versus Host Disease

Wei-Hsin Liu, Anat Globerson Levin, Assaf Lask, Galit Horn, Tova Waks, Bar Nathansohn Levy, Maksim Mamonkin, Zelig Eshhar, Richard E. Champlin, Yair Reisner, Esther Bachar Lustig

Blood (2023) 142 (Supplement 1): 4833.

https://doi.org/10.1182/blood-2023-175033

Published: 2023

Journal Articles

Splendid isolation

Dimitrios Laurin Wagner, Maksim Mamonkin

Blood (2023) 141 (22): 2665–2666.

https://doi.org/10.1182/blood.2023019864

Published: 2023

Journal Articles

Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation

Feiyan Mo, Norihiro Watanabe, Kayleigh I. Omdahl, Phillip M. Burkhardt, Xiaoyun Ding, Eiko Hayase, Angela Panoskaltsis-Mortari, Robert R. Jenq, Helen E. Heslop, Leslie S. Kean, Malcolm K. Brenner, Victor Tkachev, Maksim Mamonkin

Blood (2023) 141 (10): 1194–1208.

https://doi.org/10.1182/blood.2022016052

Published: 2023

Includes: Supplemental data

Journal Articles

Engineering naturally occurring CD7 − T cells for the immunotherapy of hematological malignancies

Blood (2022) 140 (25): 2684–2696.

https://doi.org/10.1182/blood.2021015020

Published: 2022

Includes: Supplemental data

Journal Articles

Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following CAR-T Therapy

Jay A. Read, Feiyan Mo, Maksim Mamonkin, Rayne H. Rouce, Katherine Y. King

Blood (2022) 140 (Supplement 1): 10271–10272.

https://doi.org/10.1182/blood-2022-159579

Published: 2022

Journal Articles

Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy

Alan M Williams, Ken L Hayama, Yijia Pan, Brian Groff, Rina M Mbofung, Amber Chang, Christine Chen, Lauren Fong, Nicholas Brookhouser, Berhan Mandefro, Ramzey Abujarour, Tom Lee, Maksim Mamonkin, Raedun Clarke, Ryan Bjordahl, Jode P Goodridge, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 4547–4548.

https://doi.org/10.1182/blood-2022-167139

Published: 2022

Journal Articles

CD7 CAR: sword and shield

M. Paulina Velasquez, Maksim Mamonkin

Blood (2022) 140 (4): 293–294.

https://doi.org/10.1182/blood.2022016595

Published: 2022

Journal Articles

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Blood (2022) 140 (1): 16–24.

https://doi.org/10.1182/blood.2022015728

Published: 2022

Journal Articles

A Novel Stealth Strategy That Activates Adoptively Transferred Allogeneic Immune Cells and Avoids Rejection for Off-the-Shelf Cell-Based Cancer Therapy

Alan M Williams, Ken Hayama, Yijia Pan, Brian Groff, Rina M Mbofung, Lauren Fong, Nicholas Brookhouser, Berhan Mandefro, Ramzey Abujarour, Tom Lee, Quirin Hammer, Karl-Johan Malmberg, Maksim Mamonkin, Ryan Bjordahl, Jode P Goodridge, Bahram Valamehr

Blood (2021) 138 (Supplement 1): 4800.

https://doi.org/10.1182/blood-2021-153614

Published: 2021

Journal Articles

Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma

Rayne H. Rouce, LaQuisa C. Hill, Tyler S. Smith, Lina Yang, Blakely Boriskie, Madhuwanti Srinivasan, Huimin Zhang, Silvana Perconti, Birju Mehta, Olga Dakhova, Bambi J. Grilley, Helen E. Heslop, Malcolm K. Brenner, Maksim Mamonkin

Blood (2021) 138 (Supplement 1): 654.

https://doi.org/10.1182/blood-2021-154142

Published: 2021

Journal Articles

Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia

Pinar Ataca Atilla, MD, Mary K McKenna, PhD, Norihiro Watanabe, PhD, Maksim Mamonkin, PhD, Malcolm K. Brenner, MD PhD, Erden Atilla, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141540

Published: 2020

Journal Articles

Detonating T-ALL

Maksim Mamonkin

Blood (2020) 136 (11): 1218–1219.

https://doi.org/10.1182/blood.2020006991

Published: 2020

Journal Articles

Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies

LaQuisa C. Hill, MD, Rayne H. Rouce, MD, Tyler S. Smith, Lina Yang, PhD, Madhuwanti Srinivasan, Huimin Zhang, BS, Silvana Perconti, Birju Mehta, MS, BS, Olga Dakhova, Josalind Randall, Bambi J. Grilley, RPh, Helen E. Heslop, MD DSc, Malcolm K. Brenner, MD PhD, Maksim Mamonkin, PhD

Blood (2019) 134 (Supplement_1): 199.

https://doi.org/10.1182/blood-2019-129559

Published: 2019

Journal Articles

Enhancing the Effect of CLL-1 CAR T Cells with Interleukin-15 for Treatment of Acute Myeloid Leukemia

Pinar Ataca Atilla, MD, Haruko Tashiro, MD PhD, Mary Kathryn McKenna, PhD, Madhuwanti Srinivasan, Brian Wesley Simons, Alexandra McLean Stevens, MD PhD, Michele Redell, MD PhD, Maksim Mamonkin, PhD, Malcolm K. Brenner, MD PhD, Erden Atilla, MD

Blood (2019) 134 (Supplement_1): 3912.

https://doi.org/10.1182/blood-2019-127953

Published: 2019

Journal Articles

Engineering Naturally Occurring CD7 Negative Cells for the Immunotherapy of CD7 Positive Leukemia

Abdullah Freiwan, MSc, Abishek Vaidya, MS, Caitlin Zebley, MD, Yiping Fan, PhD, Deanna Langfitt, PhD, Benjamin Youngblood, PhD, Maksim Mamonkin, PhD, Stephen Gottschalk, MD, Mireya Paulina Velasquez, MD

Blood (2019) 134 (Supplement_1): 868.

https://doi.org/10.1182/blood-2019-124903

Published: 2019

NARROW

Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL)

Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy

Targeting IDH2 R140Q and other neoantigens in acute myeloid leukemia

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

Combining Apoptotic Resistance and Cytokine Signaling to Improve Persistence and Anti-Tumor Activity of CAR Vδ2 T Cells In Vivo

Allogeneic Veto-CAR CD8 T Cells Enabling Prolonged Graft Survival, Anti-Tumor Specificity, and Low Risk of Graft Versus Host Disease

Splendid isolation

Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation

Engineering naturally occurring CD7 − T cells for the immunotherapy of hematological malignancies

Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following CAR-T Therapy

Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy

CD7 CAR: sword and shield

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

A Novel Stealth Strategy That Activates Adoptively Transferred Allogeneic Immune Cells and Avoids Rejection for Off-the-Shelf Cell-Based Cancer Therapy

Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma

Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia

Detonating T-ALL

Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies

Enhancing the Effect of CLL-1 CAR T Cells with Interleukin-15 for Treatment of Acute Myeloid Leukemia

Engineering Naturally Occurring CD7 Negative Cells for the Immunotherapy of CD7 Positive Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only